Gemini Therapeutics Signs a Research Agreement with SERI to Identify New Therapies for Age-related Macular Degeneration

Shots:

• SERI and Gemini will investigate the link b/w genetic & potential biomarkers in patients with PCV. The collaboration leverages Gemini’s experience of precision medicine to develop therapies targeting the genetically defined patients
• The agreement explores the molecular impact of specific genes linked to PCV which provide information in designing new therapies in future
• Gemini is currently working on GEM103, a recombinant Complement Factor H therapy for dry AMD which the initiation point to develop therapies targeting the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Acrofan